Idexx Laboratories Inc NASDAQ:IDXX Price, Chart, News & Insight

IDEXX Laboratories Acquires AI Veterinary Software Company CoVet

IDEXX Laboratories (NASDAQ: IDXX) has acquired CoVetAI, an AI-powered clinical workflow software provider for veterinary practices, expanding IDEXX’s growing software and artificial intelligence ecosystem. Financial terms of the transaction were not disclosed.

CoVet uses AI-powered ambient listening to automatically capture and organize information throughout veterinary consultations, treatment planning and client follow-up. Its technology can automate SOAP notes, transcribe consultations and streamline communication with pet owners, reducing administrative work for veterinarians.

The acquisition complements IDEXX’s established veterinary diagnostics and software business. More than 10,000 clinics globally already use IDEXX cloud-based practice management systems, while the company has deployed AI across diagnostic products and clinical decision-support tools. Integrating CoVet could make patient information more accessible during clinical workflows and potentially increase diagnostic utilization.

CoVet serves tens of thousands of users across North America, Europe, Australia and New Zealand and will continue supporting integrations with non-IDEXX practice management systems.

💬

WS Investor 09-16-26

IDEXX Expands Catalyst Platform With New In-Clinic Cardiac Test for Cats and Dogs

IDEXX Laboratories (NASDAQ: IDXX) announced the launch of Catalyst proBNP, a new point-of-care cardiac diagnostic test designed for both cats and dogs.

The company says Catalyst proBNP is the first dual-species in-clinic test for NT-proBNP, a biomarker used to assess heart disease. The test delivers quantitative results during a veterinary visit and will operate on IDEXX’s Catalyst platform, which has a global installed base of nearly 80,000 analyzers.

The launch also expands IDEXX into what the company estimates is an approximately $4 billion global cardiac testing opportunity. The test can support screening, diagnosis and monitoring while helping veterinarians determine when further cardiac evaluation or specialist referral may be necessary.

Catalyst proBNP is scheduled to become available in North America in October 2026, with additional international markets expected to follow.

💬

The Investor 08-11-26

IDEXX Laboratories, Inc. (NASDAQ: IDXX) will release its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens.

💬

WS Investor 04-08-26

IDEXX Laboratories reported strong fourth-quarter and full-year 2025 results, highlighting double-digit growth across key metrics and a positive outlook for 2026. Fourth-quarter revenue rose 14% year over year to $1.09 billion, driven by robust Companion Animal Group diagnostics demand and record instrument placements, while EPS increased 18% to $3.08, supported by operating margin expansion.

For the full year, revenue reached $4.30 billion, up 10%, and EPS climbed 23% to $13.08. The company also issued initial 2026 guidance, forecasting revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, reflecting continued momentum in diagnostics, innovation-driven growth, and further margin improvement.

💬

Global Finance News 02-02-26

IDEXX Laboratories, Inc announced the launch of its ImageVue DR50 Plus Digital Imaging System, a new veterinary radiography platform designed to deliver high-definition, AI-powered imaging at significantly lower radiation doses. The company said the system reduces radiation exposure by up to 25% compared with its previous ImageVue DR50 model and up to 60% versus other veterinary imaging solutions, while improving image clarity and reducing the need for retakes.

The ImageVue DR50 Plus integrates with IDEXX’s connected imaging ecosystem, including Web PACS software, telemedicine services, and practice management systems, to streamline diagnostic workflows and accelerate clinical decision-making. The system is now available to veterinary clinics in the United States and Canada, reinforcing IDEXX’s focus on advancing diagnostic quality, safety, and efficiency in veterinary care.

Source: Business Wire

💬

The Investor 01-18-26

IDEXX Laboratories announced a planned CEO succession as part of its long-term leadership transition. Michael Erickson, PhD, will be promoted to President and Chief Executive Officer effective May 12, 2026, succeeding Jay Mazelsky, who will move into the role of Executive Chair of the Board of Directors. Mazelsky plans to retire following the company’s annual shareholders’ meeting in May 2027 and will work closely with Erickson to support a smooth transition.

Erickson has been with IDEXX since 2011 and currently serves as Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine. He brings nearly 20 years of experience across diagnostics, software, strategy and healthcare innovation. As part of the transition, Erickson will also join IDEXX’s board of directors when he assumes the CEO role.

Source: IDEXX Laboratories Inc., Business Wire, January 13, 2026

💬

The Investor 01-13-26

IDEXX Laboratories announced that it will release its 2025 fourth-quarter and full-year financial results on Monday, February 2, 2026, before the U.S. market opens. An analyst conference call will follow at 8:30 a.m. ET.

💬

The Investor 01-10-26

IDEXX Lifts 2025 Outlook on Double-Digit Q3 Growth

IDEXX Laboratories (Nasdaq: IDXX) posted Q3 revenue of $1.105 billion, up 13% reported (12% organic), with CAG Diagnostics recurring revenue up 11% reported (10% organic) and over 1,700 inVue Dx placements. EPS rose 21% to $3.40, with ~100 bps operating margin expansion. The company raised 2025 guidance: revenue to $4.27–$4.30 billion (9.6%–10.3% reported; 8.8%–9.5% organic), CAG Diagnostics recurring growth to 8.3%–9.0% reported (7.5%–8.2% organic), and EPS to $12.81–$13.01 (about $0.33 higher at the midpoint).

💬

Global Finance News 11-03-25

IDEXX Shareholders Approve Governance Reforms and Director Elections at 2025 Annual Meeting

IDEXX Laboratories, Inc. held its 2025 Annual Meeting of Shareholders on May 7, during which shareholders approved significant governance changes and re-elected three Class III directors. Among the notable outcomes, investors overwhelmingly supported proposals to remove supermajority voting provisions and to adopt officer exculpation in line with updated Delaware law.

Shareholders ratified PricewaterhouseCoopers LLP as the company's auditor and approved executive compensation in an advisory vote. A shareholder proposal advocating for the annual election of directors also passed, signaling support for enhanced board accountability.

Additionally, the company filed an Amended and Restated Certificate of Incorporation eliminating its previously designated Series A Preferred Stock. Concurrently, the Board adopted revised By-Laws updating shareholder proposal procedures, forum selection clauses, and director meeting protocols.

💬

M

ME NEWS 05-12-25

IDEXX Laboratories Reports Q1 2025 Results and Raises Full-Year Outlook

IDEXX Laboratories reported first quarter 2025 revenue growth of 4% as reported and 5% organically, driven by continued strength in its Companion Animal Group (CAG) Diagnostics recurring revenue, which rose 3% as reported and 4.5% organically. Growth was supported by strong execution, including robust new business gains and global expansion of its premium instrument base, with over 300 placements of the new IDEXX inVue Dx™ system.

The company reported earnings per share (EPS) of $2.96, marking a 5% increase as reported and a 7% increase on a comparable basis. Margin improvements contributed to this growth, with gross margin expanding 90 basis points as reported and 80 basis points on a comparable basis.

IDEXX updated its 2025 guidance, raising revenue expectations to a range of $4.095 billion to $4.210 billion—an increase of approximately $40 million at the midpoint—largely due to improved foreign exchange outlooks. Full-year revenue growth is now projected at 5% to 8%, with organic revenue growth expectations held steady at 6% to 9%. CAG Diagnostics recurring revenue growth is forecasted at 4% to 7% reported, and 5% to 8% organically.

EPS guidance for 2025 has been raised to $11.93 to $12.43, up $0.19 from the prior forecast, supported by FX benefits and a favorable resolution of a litigation-related expense.

💬

Global Finance News 05-01-25

NASDAQ:IDXXFollow

NASDAQ:IDXX